261 related articles for article (PubMed ID: 25110252)
1. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.
Dulai PS; Siegel CA; Peyrin-Biroulet L
Gastroenterol Clin North Am; 2014 Sep; 43(3):441-56. PubMed ID: 25110252
[TBL] [Abstract][Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
3. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.
Ramos JM; García-Sepulcre MF; Masiá M; Brotons A; Grau MC; Gutiérrez F
Rev Esp Enferm Dig; 2010 Oct; 102(10):614-6. PubMed ID: 21039077
[No Abstract] [Full Text] [Related]
4. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
5. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
Lorenzetti R; Zullo A; Ridola L; Diamanti AP; Laganà B; Gatta L; Migliore A; Armuzzi A; Hassan C; Bruzzese V
Ann Med; 2014 Nov; 46(7):547-54. PubMed ID: 25105206
[TBL] [Abstract][Full Text] [Related]
6. Is there still a room for azathioprine monotherapy in inflammatory bowel disease?
Bourrier A; Seksik P; Cosnes J
Curr Drug Targets; 2013 Nov; 14(12):1471-9. PubMed ID: 23574282
[TBL] [Abstract][Full Text] [Related]
7. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
[TBL] [Abstract][Full Text] [Related]
8. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
[TBL] [Abstract][Full Text] [Related]
9. New strategies in the management of inflammatory bowel disease.
Rutgeerts P; Baert F
Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
[TBL] [Abstract][Full Text] [Related]
10. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
[TBL] [Abstract][Full Text] [Related]
11. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
12. Combination Immunosuppression in IBD.
Bots S; Gecse K; Barclay M; D'Haens G
Inflamm Bowel Dis; 2018 Feb; 24(3):539-545. PubMed ID: 29462391
[TBL] [Abstract][Full Text] [Related]
13. Infliximab therapy for patients with inflammatory bowel disease: 10 years on.
Van Assche G; Vermeire S; Rutgeerts P
Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S17-25. PubMed ID: 19837056
[TBL] [Abstract][Full Text] [Related]
14. Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: the first case in the literature.
Sisman G; Erzin Y; Bal K
J Crohns Colitis; 2013 Oct; 7(9):e397-8. PubMed ID: 23583098
[No Abstract] [Full Text] [Related]
15. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants.
Andrisani G; Frasca D; Romero M; Armuzzi A; Felice C; Marzo M; Pugliese D; Papa A; Mocci G; De Vitis I; Rapaccini GL; Blomberg BB; Guidi L
J Crohns Colitis; 2013 May; 7(4):301-7. PubMed ID: 22673636
[TBL] [Abstract][Full Text] [Related]
16. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
Stobaugh DJ; Deepak P
Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
[TBL] [Abstract][Full Text] [Related]
17. Medical therapy of IBD in 2009.
Harris A; Feller ER; Shah SA
Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382
[No Abstract] [Full Text] [Related]
18. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
19. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
Jones JL; Loftus EV
Inflamm Bowel Dis; 2007 Oct; 13(10):1299-307. PubMed ID: 17600819
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance in inflammatory bowel diseases.
Moreau J; Mas E
Curr Opin Pharmacol; 2015 Dec; 25():56-61. PubMed ID: 26645664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]